845273-93-0

Sevelamer carbonate (SC) is a non-absorbed phosphate binding crosslinked polymer, with the same polymeric structure as sevelamer hydrochloride, in which carbonate replaces chloride as the counterion. SC has been found to have the same safety and efficacy profile as Sevelamer HCl in HD patients.
Sevelamer carbonate(Renvela) is a nonaluminum, non-calcium-basedphosphorus binder that traps phosphorus in the bowel through ion exchange and hydrogen binding. This drug replaced sevelamer hydrochloride(Renagel) and has an advantage of not generating an acid load, as its precursor, sevelamer hydrochloride, did. It also has the advantage of lowering LDL cholesterol due to gut binding of bile acids.

Control of serum phosphorus in patients with chronic kidney disease (phosphate binder).

The Common Side Effects of Sevelamer carbonate:
Vomiting (22%), Nausea (20%), Diarrhea (19%), Indigestion (16%), Stomach pain (9%), Feeling gassy (8%), and Constipation (8%).
The Serious Side Effects of Sevelamer carbonate:
Stomach or intestine problems: bowel blockage, bleeding ulcers, severe stomach pain, blood in your stool.

Store at -20°C

The active substance in Sevelamer carbonate Winthrop, sevelamer carbonate, is a phosphate binder. When taken with meals, it attaches in the gut to phosphate from the food, thereby preventing the phosphate from being absorbed into the body and helping to reduce phosphate levels in the blood.